Highest-materiality recent filing
Allarity Therapeutics updates stenoparib manufacturing on track for Q3 2026
API manufacturing campaign on track for completion no later than Q3 2026 at GMP-compliant CDMO.
Notice of Allowance covers multiple claims for methods predicting clinical benefit and patient selection via gene expression.
Poster 2: stenoparib blocks WNT/β-catenin signaling and inhibits growth of colorectal cancer cell lines at clinically relevant concentrations.
Allarity Therapeutics FY2025 net loss $11.2M, cash $14.7M, stenoparib Fast Track
Net loss improved to $11.2M ($0.78/shr) from $25.1M ($15.65/shr) in 2024; first revenue of $320k.
Allarity closes $20M non-convertible debt with Streeterville; extends cash runway to mid-2028
Closed $20M non-convertible debt financing with Streeterville Capital via two promissory notes: $10.93M and $10M.
Allarity Therapeutics obtains $20M debt financing from Streeterville Capital with $20.93M notes
Issued $10.93M A-1 Note (9% interest) and $10M secured B Note (5% interest) for $20M purchase price.
First patients dosed with stenoparib and temozolomide in Phase 2 trial for relapsed small cell lung cancer (SCLC).
Allarity opens Phase 2 trial of stenoparib + temozolomide in relapsed SCLC
Enrollment open at 11 VA sites for NCT06681220; trial fully funded by U.S. Department of Veterans Affairs.
Median overall survival (mOS) now exceeds 25 months, not yet formally reached, in ongoing Phase 2 trial.
Allarity Therapeutics raises ~$2.5M in private placement, with option for additional $7.5M
Sold 1,562,500 shares at $1.60/sh and/or pre-funded warrants at $1.5999 for gross proceeds ~$2.5M.
Allarity receives FDA Fast Track for stenoparib in advanced ovarian cancer
FDA granted Fast Track designation to stenoparib for advanced ovarian cancer on August 26, 2025.
Allarity Therapeutics CFO resigns; appoints Jeffrey Ervin as part-time CFO effective July 1, 2025
CFO Alexander Epshinsky resigned June 30, 2025; not due to any disagreement with the company.
Allarity shareholders reject equity plan increase and officer exculpation
Thomas H. Jensen re-elected as Class III director with 1,673,698 for, 265,465 withheld.
Allarity enrolls first patient in Phase 2 stenoparib trial for advanced ovarian cancer
First patient dosed in new Phase 2 protocol for platinum-resistant or platinum-ineligible advanced ovarian cancer.
On June 10, 2025, the Board appointed Mr. Jesper Høiland as a director of the Company, effective as of June 30, 2025.
On June 5, 2025, the Board of Directors (the “ Board ”) of Allarity Therapeutics, Inc. (the “ Company ”) received the resignation of Joseph W. Vazzano as director of the Company, effective June 30, 2025.
Max materiality 0.75 · Median 0.60 · Most common event other_material